Equity Profile

HALO

Halozyme Therapeutics, Inc.

Health CareBiotechnology$8.5B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, critical for sustaining long-term growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

HALO Q2-2026 Earnings Preview

Context

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases. Operating in the health care sector, Halozyme is known for its proprietary enzyme technology that enhances the delivery of biologic drugs, which is increasingly important as the demand for effective treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+5.95%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In Q1-2026, Halozyme reported an EPS of $1.60, surpassing expectations by 9.74%. The stock reacted positively, gaining 3.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Halozyme's upcoming earnings, especially given its strong EPS performance in recent quarters.

Bull Case

If Halozyme continues its trend of beating EPS estimates, it could see significant stock appreciation, especially if revenue growth is also strong.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter?

Given the company's strong track record of beating EPS estimates, this will be a critical indicator of ongoing financial health.

How is revenue growth trending?

Revenue growth is essential for assessing the company's ability to sustain its operations and invest in future innovations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Halozyme to exceed EPS expectations based on its recent performance trends.

Supporting Evidence

Halozyme has consistently beaten EPS estimates in recent quarters, with an 88% beat rate.

The options market is pricing in a significant move, suggesting that traders expect volatility and potential upside.

Insider buying activity indicates confidence in the company's future prospects.

Key Risk

If EPS comes in below $1.40, it could undermine the bullish narrative and lead to a reevaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Halozyme's ability to maintain its earnings momentum and revenue growth, which are critical for investor confidence.

Bull Confirmed If

An EPS of $1.70 or higher would confirm the bullish sentiment and suggest strong operational performance.

Bear Confirmed If

An EPS below $1.40 would likely confirm bearish sentiment and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±15.76%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±15.8% while HALO has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

32.9%

Calls (32K)P/C Ratio: 0.10Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Halozyme beats expectations, history suggests a potential stock increase of around 0.49%, confirming strong operational performance.

In-Line / Cautious

If the results are in line with expectations, the market may react cautiously, leading to minimal movement as investors digest the news.

Miss

If the company misses expectations, history suggests a potential decline of around 1.31%, which could raise concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or partnerships.
2Insights into market demand for Halozyme's therapies.
3Management's outlook on revenue growth for the next quarter.
4Details on cost management and operational efficiencies.
5Any commentary on competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, critical for sustaining long-term growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

HALO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+5.95%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In Q1-2026, Halozyme reported an EPS of $1.60, surpassing expectations by 9.74%. The stock reacted positively, gaining 3.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Halozyme's upcoming earnings, especially given its strong EPS performance in recent quarters.

Bull Case

If Halozyme continues its trend of beating EPS estimates, it could see significant stock appreciation, especially if revenue growth is also strong.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter?

Given the company's strong track record of beating EPS estimates, this will be a critical indicator of ongoing financial health.

How is revenue growth trending?

Revenue growth is essential for assessing the company's ability to sustain its operations and invest in future innovations.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Halozyme to exceed EPS expectations based on its recent performance trends.

Supporting Evidence

Halozyme has consistently beaten EPS estimates in recent quarters, with an 88% beat rate.

The options market is pricing in a significant move, suggesting that traders expect volatility and potential upside.

Insider buying activity indicates confidence in the company's future prospects.

Key Risk

If EPS comes in below $1.40, it could undermine the bullish narrative and lead to a reevaluation of the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Halozyme's ability to maintain its earnings momentum and revenue growth, which are critical for investor confidence.

Bull Confirmed If

An EPS of $1.70 or higher would confirm the bullish sentiment and suggest strong operational performance.

Bear Confirmed If

An EPS below $1.40 would likely confirm bearish sentiment and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±15.76%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±15.8% while HALO has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

32.9%

Calls (32K)P/C Ratio: 0.10Puts (11K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Halozyme beats expectations, history suggests a potential stock increase of around 0.49%, confirming strong operational performance.

In-Line / Cautious

If the results are in line with expectations, the market may react cautiously, leading to minimal movement as investors digest the news.

Miss

If the company misses expectations, history suggests a potential decline of around 1.31%, which could raise concerns about future growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or partnerships.
2Insights into market demand for Halozyme's therapies.
3Management's outlook on revenue growth for the next quarter.
4Details on cost management and operational efficiencies.
5Any commentary on competitive pressures in the biotechnology sector.